Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subject Adherence and Satisfaction for Loceryl vs Ciclopirox in Onychomycosis
NCT02679911Phase 4Completed
- Sponsor
- Galderma
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amorolfine in onychomycosis (2 arms), sponsored by Galderma. Primary endpoint: Percent of "in Label" Adherent Subjects at 12 weeks. Started Sep 2015; status: completed.
02
Drugs
amorolfine
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT02679911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02679911.